Amgen’s Aranesp v. Procrit Promotional Claims Result In Off-Label Guilty Plea
This article was originally published in The Pink Sheet Daily
Amgen pled guilty to marketing Aranesp off-label as part of a global settlement with the government; the final agreement, expected to be approved on Dec. 19, could involve marketing practices of Enbrel and six other drugs.
You may also be interested in...
OCI Director John Roth set to depart upon his confirmation to Homeland Security Department post.
Amgen’s direct mailer featuring the image of a man in free fall misleading suggests Aranesp is useful in a broader patient population than it is indicated for, agency says.
Pfizer finalizes a $55 million settlement with the Department of Justice concerning Wyeth’s Protonix promotional practices; a separate probe of alleged bundling of Protonix sales to hospitals continues.